ArticleTrials2021

A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.

T Fields et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.